• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过放射受体分析法测定,奎尼丁对立体选择性微粒体结合位点具有高亲和力。

High affinity of quinidine for a stereoselective microsomal binding site as determined by a radioreceptor assay.

作者信息

Otton S V, Kalow W, Seeman P

出版信息

Experientia. 1984 Sep 15;40(9):973-4. doi: 10.1007/BF01946465.

DOI:10.1007/BF01946465
PMID:6468627
Abstract

The techniques of the radioreceptor binding assay were applied to detect stereoselective binding of quinidine and quinine to a site on human liver microsomes. Binding of 3H-dihydroquinidine was 50% inhibited by 20-100 nM quinidine, while its enantiomer quinine did not displace the 3H-ligand at concentrations up to 500 nM. This stereoselectivity agreed with the affinity values measured by functional enzyme assays of cytochrome P450 activity using sparteine or debrisoquine as substrates.

摘要

采用放射受体结合分析技术检测奎尼丁和奎宁与人肝微粒体上某一位点的立体选择性结合。20 - 100 nM的奎尼丁可抑制3H - 二氢奎尼丁50%的结合,而其对映体奎宁在浓度高达500 nM时不能取代3H配体。这种立体选择性与使用司巴丁或异喹胍作为底物通过细胞色素P450活性功能酶分析测得的亲和力值一致。

相似文献

1
High affinity of quinidine for a stereoselective microsomal binding site as determined by a radioreceptor assay.通过放射受体分析法测定,奎尼丁对立体选择性微粒体结合位点具有高亲和力。
Experientia. 1984 Sep 15;40(9):973-4. doi: 10.1007/BF01946465.
2
Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.利用奎尼丁抑制作用来确定司巴丁/异喹胍细胞色素P450在人肝微粒体对美托洛尔氧化中的作用。
J Pharmacol Exp Ther. 1988 Oct;247(1):242-7.
3
The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins.大脑中的多巴胺转运体和细胞色素P45OIID1(异喹胍4-羟化酶):两种不同的[3H]GBR-12935结合蛋白的解析与鉴定。
Arch Biochem Biophys. 1990 Feb 1;276(2):424-32. doi: 10.1016/0003-9861(90)90741-g.
4
Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes.大鼠微粒体和完整肝细胞中放射性标记右美沙芬的去甲基化作用
Eur J Biochem. 2003 Sep;270(18):3768-77. doi: 10.1046/j.1432-1033.2003.03763.x.
5
Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.人类细胞色素P450 3A参与奎宁3-羟基化作用的证据。
Br J Clin Pharmacol. 1997 Mar;43(3):245-52. doi: 10.1046/j.1365-2125.1997.00556.x.
6
In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.关于人肝脏中司巴丁/异喹胍单加氧酶对奎尼丁氧化作用的体外证据。
Drug Metab Dispos. 1988 Jan-Feb;16(1):15-7.
7
[Stereoselectivity in O-demethylation of trans tramadol in rat liver microsomes in vitro].[大鼠肝微粒体体外对反式曲马多O-去甲基化的立体选择性]
Yao Xue Xue Bao. 2002 Mar;37(3):169-74.
8
Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites.
Biochem Pharmacol. 1995 Sep 7;50(6):833-7. doi: 10.1016/0006-2952(95)00207-g.
9
Oxidation of quinidine by human liver cytochrome P-450.奎尼丁被人肝脏细胞色素P-450氧化。
Mol Pharmacol. 1986 Sep;30(3):287-95.
10
Stereoselective renal tubular secretion of quinidine and quinine.奎尼丁和奎宁的立体选择性肾小管分泌
Clin Pharmacol Ther. 1986 Nov;40(5):511-7. doi: 10.1038/clpt.1986.216.

本文引用的文献

1
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.司巴丁N-氧化缺陷与异喹胍4-羟化的药物遗传学共变。
Eur J Clin Pharmacol. 1980 Feb;17(2):153-5. doi: 10.1007/BF00562624.
2
Deficient metabolism of debrisoquine and sparteine.异喹胍和鹰爪豆碱代谢缺陷。
Clin Pharmacol Ther. 1980 Apr;27(4):547-9. doi: 10.1038/clpt.1980.77.
3
E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.去甲替林的E型和Z型10-羟基化作用:与异喹胍多态性羟基化作用的关系。
Clin Pharmacol Ther. 1981 Aug;30(2):189-93. doi: 10.1038/clpt.1981.147.
4
Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.人体肝脏中去甲丙咪嗪4-羟化酶缺陷的证据。
Br J Clin Pharmacol. 1981 Jan;11(1):89-91. doi: 10.1111/j.1365-2125.1981.tb01108.x.
5
Oxidation phenotype--a major determinant of metoprolol metabolism and response.氧化表型——美托洛尔代谢及反应的主要决定因素。
N Engl J Med. 1982 Dec 16;307(25):1558-60. doi: 10.1056/NEJM198212163072505.
6
In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine.人肝脏对司巴丁的体外代谢:地昔帕明的竞争性抑制作用。
Can J Physiol Pharmacol. 1982 Jan;60(1):102-5. doi: 10.1139/y82-017.
7
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.鹰爪豆碱和异喹胍的多态性氧化:相关药物遗传学实体。
Clin Pharmacol Ther. 1982 Feb;31(2):184-6. doi: 10.1038/clpt.1982.29.
8
Defective oxidation of drugs: pharmacokinetic and therapeutic implications.药物氧化缺陷:药代动力学及治疗学意义
Clin Pharmacokinet. 1982 Jan-Feb;7(1):1-22. doi: 10.2165/00003088-198207010-00001.
9
Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs.三环类抗抑郁药及其他药物对人肝脏中鹰爪豆碱氧化的抑制作用。
Life Sci. 1983 Feb 14;32(7):795-800. doi: 10.1016/0024-3205(83)90315-6.
10
Comparative pharmacogenetics of sparteine and debrisoquine.鹰爪豆碱和异喹胍的比较药物遗传学
Clin Pharmacol Ther. 1983 Mar;33(3):394-9. doi: 10.1038/clpt.1983.51.